Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

Biomarkers are the molecules which indicate normal/abnormal process taking place in the body and might be the sign of an underlying condition or disease. Various types of molecules can serve as biomarkers, such as DNA (genes), proteins or hormones since they all indicate the status of your health. Biomarkers take part in various processes like disease diagnosis and prognosis, prediction and calculation of treatment response, and also safety evaluation. The molecular biomarkers are exclusively being developed and validated to be used in drug development, and are used to support approval of drug products.

  • Track 1-1Molecular biomarkers
  • Track 1-2Cancer biomarkers
  • Track 1-3Lipid biomarkers
  • Track 1-4Oncology biomarkers
  • Track 1-5Neurological biomarkers
  • Track 1-6Inflammatory & immunological biomarkers
  • Track 1-7Cardiovascular biomarkers
  • Track 1-8In-silico biomarkers

Biomarkers have a very important role in the field of medical research providing insight into the mechanism & course of any disease. Regardless of their role, clinical significance depending on their sensitivity, specificity, predictive value, & even precision, reliability, reproducibility, and also the possibility of  wide application. There are numerous clinical applications of Biomarkers in the treatment of diseases such as cardiovascular, acute kidney injuries, and cancer treatments. The Biomarkers are even used in development of vaccines and drug which is a major application in the field.

  • Track 2-1Clinical Applications in Cardiovascular diseases
  • Track 2-2Application of Biomarkers in the development of drugs
  • Track 2-3Vaccine and drug development
  • Track 2-4Other Applications of Biomarkers

Current genomics & biotechnology techniques promise development of biomarkers for predicting individual disease risk which enables the early detection of disease and improved diagnostics classification towards better & informed individualized treatment. Biomarkers are the biological measurements which are used for predicting the risk of diseases for enabling early detection of disease.

  • Track 3-1Validation and qualification of genomic biomarkers
  • Track 3-2Database of genomic biomarkers
  • Track 3-3Early detection biomarkers
  • Track 3-4Treatment selection biomarkers
  • Track 3-5Genomic medicine

Transcriptomics : study of the RNA transcripts which are produced by the genomes using high-throughput techniques. Transcriptional profiling is the technique used for identifying the differences in gene expression between the diseased tissues and the healthy tissues. DNA sequencing, mRNA profiling, Proteomics, and Systems Biology help in the analysis of the transcriptional profiling. ESTs and DNA microarrays are the techniques that are used in Transcriptional profiling.

  • Track 4-1Gene expression analysis in biomarker research
  • Track 4-2Transcription analysis and transcriptional profiling
  • Track 4-3Microarray data analysis
  • Track 4-4Comparison to proteomics
  • Track 4-5Limitations of profiling
  • Track 4-6Technologies for transcriptional profiling
  • Track 4-7Gene Annotation

The major usage of biomarkers in clinical investigation is in the form of clinical trials & monitoring. The entire spectrum of disease from the earliest indication till the terminal stages may be resonated through these biomarkers. Biomarker shows the best relationship between its response when it is compared to the health/ecological effect. It provides variety of human and animal materials principally through immuno-assays and quantitative PCR that can be analytically determined at any of the Biomarker Laboratory.

  • Track 5-1Biomarker requirements
  • Track 5-2Development of biomarkers for drug safety
  • Track 5-3Phases of biomarker development
  • Track 5-4Disease-related biomarkers and drug-related biomarkers

Pathology in the assessment of bosom malignancy is with the aid of biomarker testing. These are particularly the precise appraisal of the estrogen receptor, progesterone receptor. Biomarkers can be prognostic, prescient, or even both. Prognostic biomarkers are free measures for forecasting such extent that the nearness or nonappearance of the biomarker is connected with a patient's general clinical result (i.e., danger of repeat and mortality).

  • Track 6-1Biomarkers in anatomic pathology
  • Track 6-2Molecular biomarkers of knee pathology
  • Track 6-3Molecular pathology and biomarkers
  • Track 6-4Diagnostic and predictive biomarkers
  • Track 6-5Biomarkers of alzheimer’s disease pathology
  • Track 6-6Tumor molecular pathology

Next-generation sequencing involved in DNA sequencing and RNA sequencing is quicker and cheaper than the old methodology and also there is a revolution in the study of genomics and molecular biology due to this. Genetic-based biomarkers are the biomarkers the ones involved in the process of representing genes and gene products as the biomarkers. Genome sequencing using next-gen sequencing helps in the discovery of biomarkers.

  • Track 7-1Genome biomarkers
  • Track 7-2Cell proliferation markers
  • Track 7-3Cytogenetic biomarkers
  • Track 7-4Oxidative stress biomarkers
  • Track 7-5Next-generation sequencing for the discovery of Biomarkers
  • Track 7-6Genome sequencing for the discovery of Biomarkers
  • Track 7-7MicroRNA sequencing for the prediction of diseases
  • Track 7-8Using SNP as biomarkers

Bioethics is the investigation of commonly questionable moral issues which are rising up out of new circumstances & potential outcomes which are realized by advances in medication. It is in addition moral insight as it identifies the therapeutic approach, practice, and research. Bioethicists are worried with moral inquiries which emerge in relation with life sciences, biotechnology, prescription, clinical research, reasoning and so forth. a

  • Track 8-1Bioethics: Case studies and ethical regulatory guidelines
  • Track 8-2Ethics and patients rights
  • Track 8-3Ethics & Human subject protection
  • Track 8-4Value of ethics in clinical research
  • Track 8-5New regulatory flexibility driving positive industry change
  • Track 8-6Bridging regulations to Real-World health care
  • Track 8-7Ethical challenges in cancer clinical trials
  • Track 8-8Compliance and regulatory requirements in clinical research

Biomarkers provides dynamic & powerful approach in understand of diseases with applications in observational & analytical epidemiology, randomized clinical trials, screening, and diagnosis. Biomarkers reflects entire spectrum of disease from the earliest manifestations till the terminal stages.  Biomarkers play an important role in various cardiovascular, neurological and rheumatic diseases which were incurable since a very long. Biomarkers have brought revolution in prediction, diagnosis & treatment of the diseases that were difficult to handle before.

  • Track 9-1Biomarkers for Alzheimers
  • Track 9-2Biomarkers for cardiovascular diseases
  • Track 9-3Biomarkers for cardiovascular diseases
  • Track 9-4Biomarkers for neurodegenerative diseases
  • Track 9-5Biomarkers for diabetes
  • Track 9-6Biomarkers for huntington diseases
  • Track 9-7Biomarkers for other diseases
  • Track 9-8Biomarkers in psychiatry

Biomarkers have gained immense scientific value and interest in the practice of medicine. They are potentially useful in the whole spectrum of disease process The ability of biomarkers in improved treatment and reduced health-care costs is potentially greater than in any other area of current medical research. The latest innovations and emerging technologies are leading to the further advancements and enhancements in the various fields. 

  • Track 10-1Biomarker research in Neurology
  • Track 10-2Cell Free Biomarkers
  • Track 10-3Challenges in Biomarkers research
  • Track 10-4Biomarkers of Environmental Pollutants
  • Track 10-5Genomic and proteomic approaches
  • Track 10-6Metabolomics and metabonomics methods
  • Track 10-7Transcriptomics for the discovery of Biomarkers

The aim of drug discovery and development is to identify effective drug and provide it in right dosage at right frequency to affected organism. Biomarkers are effective tool to identify the mechanism of action of the drug that can correlate pharmacokinetics and pharmacodynamics (PK & PD) of drug. Biomarkers aids in finding the safe procedure of drug administration. In genomics, the biomarker challenge identifies unique molecular signatures in complex biological mixtures which unambiguously correlate to biological events for validating novel drug targets and also predict drug response. 

  • Track 11-1Biomarker discovery and Identification methods
  • Track 11-2Translational biomarkers in drug development
  • Track 11-3Biomarker discovery and clinical validations
  • Track 11-4Biomarkers and new therapeutic strategies
  • Track 11-5Novel technologies in drug discovery
  • Track 11-6Novel technologies in drug discovery
  • Track 11-7Why formulation and delivery strategies fail
  • Track 11-8Experimental and computational approaches

Clinical trials are research studies that aid to explore medical strategy, treatment method, or device .i.e. safe and effective for humans. These studies may show which medical approaches works best for certain illnesses or groups of people. Clinical trials produce the best data available for health care decision making. The purpose of clinical trials is research on the methods and procedures so that the studies follow strict scientific standards. These standards protect patients and help to produce reliable decisions on the study results.

  • Track 12-1Clinical study designs
  • Track 12-2In Vitro and In Vivo studies
  • Track 12-3Phases & types of clinical trials
  • Track 12-4Surgical clinical trials
  • Track 12-5Investigational new drug process
  • Track 12-6Drug discovery and development

Modern pharmaceuticals & medical devices have provided substantial benefits to numerous patients throughout the world. These benefits come at a very high cost. Appropriate use of the imaging biomarker with imaging methods can be used to establish the presence & severity of disease and also offer the prospect of smaller, less expensive, & more efficient preclinical studies and clinical trials. Scientists, government regulators, and industry have recognized the potential of biomarkers in the field of imaging. Even though radiological sciences have long history in the medical field, Imaging Biomarkers have given it a new turn. In the modern day radiology, biomarkers have an undividable integral part which has become the major reason for the latest developments in this field.

  • Track 13-1Imaging biomarkers
  • Track 13-2Quantitative imaging biomarkers
  • Track 13-3Clinical imaging
  • Track 13-4Cancer screening
  • Track 13-5Screening for other diseases
  • Track 13-6New generation tools and technologies

Biomarkers are intended to replace surrogate endpoints in clinical trials process. Surrogate markers are used to conduct clinical trial and gather a number of endpoints which is impractical when the primary end point is undesired or the event number is small. Biomarkers help in the diagnostics and clinical development processes. Biomarkers case study plays an important role in finding new treatments for the patients who need new drugs and to be used widely in various clinical practices.

  • Track 14-1Case reports on molecular biomarkers
  • Track 14-2Case reports on cancer biomarkers
  • Track 14-3Case reports on diagnostics
  • Track 14-4Case reports on drug discovery
  • Track 14-5Case reports on imaging

Personalized Medicine is known for its use of genomic information in addition to the family history, environmental factors and lifestyle to manage the health. Accurate predictions can be made about a person’s susceptibility to develop a disease, the course of disease and to respond to the treatment. Personalized Medicine is a new field of research and evidence-based literature is required for integrating into healthcare delivery.

  • Track 15-1Drug development and usage
  • Track 15-2Cancer genomics
  • Track 15-3Challenges and probable solutions
  • Track 15-4Tumour biomarkers
  • Track 15-5Diagnostic and prognostic biomarkers
  • Track 15-6Diagnosis and intervention

Biomarker research is a continuous process beginning with discovery & then proceeds to validation process till the implementation of biomarkers in the clinical setting.  Candidate biomarkers which are identified in discovery stage need to be validated across the number of samples. The challenge is to develop a fast and targeted analysis method that is capable of analyzing as many identified candidates as possible in minimum hundred and potentially even thousands of samples. Biomarker candidates identified during discovery process are validated using larger samples which covers a broad section of patients. The verification stage provides confirmation that a particular methodology is suitable to be used in the validation phase.

  • Track 16-1Omics Technologies in Biomarkers Discovery and Validation
  • Track 16-2Latest diagnosis techniques
  • Track 16-3Assessment of drug response
  • Track 16-4Application of tools
  • Track 16-5Advancements in analysis

With increasing initiatives for improving the effectiveness and safety of patient care, there is a growing emphasis on evidence-based medicine and incorporation of high-quality evidence into clinical practice. The various procedures to be followed for Clinical Research & Methodology will be summed up in this session. Explanatory clinical studies are the most widely accepted and executed type of trials. They explain the therapeutic aspects of a drug and also provide a detailed description on adverse events and PV. Any new drug that is to be marketed initially requires proving its safety, efficacy and the need over the existing product by going through various phases of a clinical trial that follows animal studies.

  • Track 17-1Quality regulation
  • Track 17-2GCP & GMP
  • Track 17-3Registry of clinical trials
  • Track 17-4Designing clinical research
  • Track 17-5Principles and practice of clinical research
  • Track 17-6Conducts of Clinical Trial

CDM is the back bone of every successful clinical trial. Considering the complexity of operational aspects of the process, it is necessary to check the quality of data and also analysis of trend across the site(s). Clinical Data Management is the process of handling the data received from various clinical trials. The inherent goal of any clinical data management system is to produce & maintain the quality data. CDM being the critical phase in the process of clinical research leads to generation of high-quality, reliable, and statistically sound data from the clinical trials.

  • Track 18-1Artificial intelligence in clinical research
  • Track 18-2Tools for CDM
  • Track 18-3Review and finalization of study documents
  • Track 18-4Database designing
  • Track 18-5Standard operating procedures
  • Track 18-6Database design and build
  • Track 18-7Big data for clinical trials

Pharmacovigilance & Risk Management was designed for providing an understanding of risk management in healthcare operations and applications. Pharmacovigilance is defined as the science and the activities relating to the detection, assessment, understanding and even prevention of adverse effects or any other drug-related issue.  The aims of PV is to enhance patient care and patient safety in relation to usage of medicines.

  • Track 19-1Pharmacovigilance and Risk Management
  • Track 19-2Ecopharmacovigilance
  • Track 19-3PV: Current regulation & challenges
  • Track 19-4Pharmacovigilance significance & scope
  • Track 19-5PV consulting’s and business opportunity
  • Track 19-6Adverse drug reactions

Biomarkers are used in the treatment of cancer, and as an aid in clinical decision making about which anti-cancer therapy is to be used in any particular patient. Biomarkers play a significant role in cancer prognosis, diagnosis, and treatment. There are a number of cancers which are hard to diagnose. The latest designed biomarkers & their applications are an added advantage in these kinds of cases. Cancer Epidemiology, treatment and latest research is greatly relayed on these biomarkers. Clinical molecular diagnostics & biomarker discoveries in oncology are advancing at a very faster rate. There is an urgent need to understand the complex mechanisms that transform a normal cell into abnormal one. These discoveries have added fuel in the development of novel drug targets & the latest treatment strategies.

  • Track 20-1Biomarkers for lung cancer
  • Track 20-2Biomarkers for prostate cancer
  • Track 20-3Biomarkers for blood cancer
  • Track 20-4Biomarkers for adrenal cancer
  • Track 20-5Biomarkers for colorectal cancer
  • Track 20-6Biomarkers for gastric cancer

The clinical trials are the scientific studies of effects, risks, efficacy & benefits of new and even existing medicines. Trials are supposed to be carried out before a product reaches the hospital or local pharmacy. They are undertaken at various stages, or say ‘phases’, and include trials on healthy individuals; patients with a disease; & also studies conducted after the launch of the new product to monitor safety and side effects during large-scale use. Clinical trials are conducted by pharmaceutical companies or Contract Research Organisations on their behalf. There are various roles and responsibilities in these phases of Clinical Trials.

  • Track 21-1Clinical CROs
  • Track 21-2BA/BE Centers
  • Track 21-3SMOs
  • Track 21-4Data Management
  • Track 21-5IT Companies in Healthcare/Clinical Domains
  • Track 21-6Central Laboratories
  • Track 21-7Packaging & Labeling
  • Track 21-8 Investigator & Site Staffs

CRO provides support to the pharma industries in the form of research services outsourced on contract basis. In the conduct of clinical trials, a sponsor is an individual/institution/company/ organization that takes responsibility to initiate, manage or finance clinical trial, but it actually does not conduct the investigation. The sponsor is responsibility is for implementing & maintaining QA and QC systems with written SOPs so as to ensure that trials are conducted and data is generated, documented, and reported in compliance with the protocol, GCP, and the applicable regulatory requirement.

  • Track 22-1Challenges and opportunities of sponsors and CROs
  • Track 22-2Hidden costs for sites and sponsors
  • Track 22-3CRO selection and management
  • Track 22-4Financial aspects of clinical trials
  • Track 22-5Business development tactics

Clinical trials are the safest and fastest method to determine any new medical approaches for HIV prevention/ treatment are safe and effective in individuals. All the medicines used to prevent and treat HIV in the United States were initially studied in clinical trials.

There are several types of cancer clinical trials, Each type of trial is designed to answer different research questions and will help researchers learn things that will help people in the future.

Diabetes/Diabetes mellitus describes a group of metabolic diseases in which the person has high glucose, either because insulin production is inadequate, or because the body's cells do not respond to insulin, or both. Clinical trials are conducted for both the Type 1 and Type 2 diabetes.

  • Track 23-1Clinical research and Trials on HIV/AIDS
  • Track 23-2Oncology clinical trials
  • Track 23-3Breast cancer research and trials
  • Track 23-4Diabetes Mellitus Type 1 Clinical Trials
  • Track 23-5Diabetes Mellitus Type 2 Clinical Trials
  • Track 23-6Brain, Spine, Lung, Kidney, Blood, Skin and all other cancers research and trials

The globalization of clinical research is a recent phenomenon, in which a number of studies is taking place on a global scale, with a significant increase of clinical trials in developing countries. Developed markets in the USA, Europe, Germany, and Japan still generate the large share of clinical trial activity. According to the report China, Japan, India, and Korea are the most active sites for clinical trials among developing nations.

  • Track 24-1Globalization of drug development
  • Track 24-2Japan clinical trials
  • Track 24-3Strategies for successful globalization of clinical trials
  • Track 24-4USA clinical trials
  • Track 24-5Mutual recognition of clinical study results
  • Track 24-6Comparative impact of globalization
  • Track 24-7Ethical and scientific implications
  • Track 24-8Asia clinical trials
  • Track 24-9UK clinical trials